The role of deubiquitinase USP33 in colorectal cancer tumorigenesis and its potential as a therapeutic target predictor

Deubiquitination(DUB) is a critical cellular process that regulates protein stability and functionality, playing essential roles in cell proliferation, migration, tumorigenesis, and various molecular signaling pathways. Within the DUB enzyme family, ubiquitin-specific protease 33 (USP33) is found to be aberrantly expressed in several cancers, including a significant reduction in colorectal cancer (CRC) tissues. The decreased expression of USP33 impairs its ability to inhibit CRC cell proliferation, migration, and invasion, potentially through its involvement in key signaling pathways such as the β-arrestin-dependent ERK pathway, Slit-Robo pathway, and Wnt/β-catenin pathway. This review highlights the interaction between USP33 and these signaling pathways, exploring its potential as a novel independent prognostic biomarker for CRC and its promise as a therapeutic target.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-02-09
DOI
https://doi.org/10.1007/s12672-026-04546-8
Primary Topic
Ubiquitin and proteasome pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The role of deubiquitinase USP33 in colorectal cancer tumorigenesis and its potential as a therapeutic target predictor

Jianmin Wu, Heng Wu, Li Zhang, Yu Dai et al.
Discover Oncology
Ubiquitin and proteasome pathways
article

The role of deubiquitinase USP33 in colorectal cancer tumorigenesis and its potential as a therapeutic target predictor

Jianmin Wu, Heng Wu, Li Zhang, Yu Dai, Xinyu Luo, Zijian Deng, Jin Yan, Yajun Luo
article en

Abstract

Deubiquitination(DUB) is a critical cellular process that regulates protein stability and functionality, playing essential roles in cell proliferation, migration, tumorigenesis, and various molecular signaling pathways. Within the DUB enzyme family, ubiquitin-specific protease 33 (USP33) is found to be aberrantly expressed in several cancers, including a significant reduction in colorectal cancer (CRC) tissues. The decreased expression of USP33 impairs its ability to inhibit CRC cell proliferation, migration, and invasion, potentially through its involvement in key signaling pathways such as the β-arrestin-dependent ERK pathway, Slit-Robo pathway, and Wnt/β-catenin pathway. This review highlights the interaction between USP33 and these signaling pathways, exploring its potential as a novel independent prognostic biomarker for CRC and its promise as a therapeutic target.

Discover OncologyVol. 17(1)
Southwest Medical University (CN), Chengdu Sport University (CN), Affiliated Hospital of Southwest Medical University (CN), Sichuan Cancer Hospital (CN)
Good health and well-being
Openalex Percentile: Top 63%
Ubiquitin and proteasome pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The role of deubiquitinase USP33 in colorectal cancer tumorigenesis and its potential as a therapeutic target predictor — Jianmin Wu, Heng Wu, et al. · Discover Oncology (2026) | TGRS Research Map | TGRS